Latest Conference

Results show medication provides therapeutic response for Candida.

In an effort to expand serotype coverage beyond 13, a 20-valent pneumococcal conjugate vaccine, PCV20, is currently in development.

Overall, 88% of participants who received long-acting therapy preferred CAB LA+RPV LA compared with oral treatment.

The results support B/F/TAF as a switch option for Black Americans who are virologically suppressed, including individuals with a history of treatment failure or pre-existing resistance.

How has the COVID-19 pandemic affected clinical trial site restrictions, drug delivery, dosing, patient monitoring, and follow-up?

New data presented at IDWeek showed more than half observed households with a COVID-19 case reported a secondary infection, oftentimes within 3 days.

Phase 1 data and a history of benefit for worsening respiratory infections show promise for the therapy.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

In a large nursing home study, asymptomatic and symptomatic residents were found to carry similar viral loads.

A study looked at weight gain when changing therapy regimens.

Sulopenem was superior to ciprofloxacin for the treatment of uncomplicated urinary tract infections.

In a phase 1/2 randomized clinical trial, GlaxoSmithKline’s RSVPreF3 vaccine elicits a response.

The composition of the gut microbiome is easily disrupted by antibiotics, leaving the host susceptible to further infection or other disturbance of gut flora that can lead to both short- and long-term deleterious effects.

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

In results of a national survey, investigators pieced together a look at the psychological toll of the pandemic on physicians and identified the biggest stressors.

The CovidIQ tool successfully predicted a COVID-19 spike in Jacksonville, Florida, a full 2 weeks before it was recognized by the Florida Department of Health.

Antimicrobial-resistant infections, in particular those caused by gram-negative pathogens that also produce extended spectrum β-lactamases (ESBL), represent a growing threat across the globe as investigators race to develop novel therapeutics

Why it's critical for the future of HIV prevention for programs like the California PrEP-AP to reach younger at-risk persons now.

How a sexually-transmitted virus is hindered by limited marketing, and how its stigmas compare to those developing around COVID-19.

Why men who have sex with men face social hurdles in seeking PrEP and preventive education.

How regional-based data and advancing preventive options could bolster individual HIV-risk care access.

Findings were announced during the special COVID-19 sessions of the virtual 23rd International AIDS Conference.

A study looking at PrEP population obstacles shows men who have sex with men are more likely to not seek out information nor access to prophylaxis.

Dr. Marc Pitasi, epidemiologist, discusses facilitators of routine HIV screening among primary care physicians.

A small study shows a majority of HIV patients open to both starting ART and follow-up telehealth appointments.

A discussion around new data presented at AIDS 2020 which shows statewide strategies are breaking down barriers.

Investigators in Tanzania trialed modest, automated financial incentives for clinic attendance on viral suppression for patients initiating ART.

In a large study, an examination of patterns of use.